neurodegenerative disorders
Grifols share results identifying early signs of Parkinson’s disease
Parkinson’s disease affects over six million people globally
Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease
Planning is currently underway for a placebo-controlled trial of the candidate
Roche to advance Parkinson’s disease candidate into phase 3 development
More than ten million people worldwide are living with the neurodegenerative disorder
UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis
It is hoped that the test could be available for widespread UK use in the coming years
FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate
The progressive neurodegenerative disease affects more than ten million people worldwide
International Alzheimer’s disease prevention trial in at-risk young adults begins
The study will evaluate whether the amyloid beta protein can be blocked from ever accumulating in the brain
FDA approves Supernus Pharmaceuticals’ Onapgo to treat advanced Parkinson’s disease
The neurodegenerative disorder affects almost one million people in the US
AbbVie’s Parkinson’s disease candidate tavapadon shows promise in phase 3 trial
More than ten million people worldwide are living with the neurodegenerative disorder
UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab
The drug showed benefits across key secondary endpoints, including tau accumulation
AbbVie’s continuous Parkinson’s disease therapy Vyalev approved by FDA
More than ten million people worldwide are living with the neurological disorder
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
Approximately 153,000 people in the UK are currently living with the neurodegenerative disorder
Study reveals inflammation caused by infections could contribute to MS progression
The progressive, neurodegenerative disease is estimated to affect more than 130,000 people in the UK